These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 24942978)

  • 21. Synthesis and biological evaluation of pyrrolo[2,3-b]pyridine analogues as antiproliferative agents and their interaction with calf thymus DNA.
    Narva S; Chitti S; Bala BR; Alvala M; Jain N; Kondapalli VG
    Eur J Med Chem; 2016 May; 114():220-31. PubMed ID: 26994690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel FMS inhibitors.
    Kim YY; Choi J; Choi K; Park C; Kim YH; Suh KH; Ham YJ; Jang SY; Lee KH; Hwang KW
    Bioorg Med Chem Lett; 2019 Jan; 29(2):271-275. PubMed ID: 30522957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ethyl 2-(benzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine-6-carboxylate analogues as a new scaffold for protein kinase casein kinase 2 inhibitor.
    Jin CH; Jun KY; Lee E; Kim S; Kwon Y; Kim K; Na Y
    Bioorg Med Chem; 2014 Sep; 22(17):4553-65. PubMed ID: 25131958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclosquaramides as kinase inhibitors with anticancer activity.
    Villalonga P; Fernández de Mattos S; Ramis G; Obrador-Hevia A; Sampedro A; Rotger C; Costa A
    ChemMedChem; 2012 Aug; 7(8):1472-80. PubMed ID: 22777958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.
    Brasca MG; Albanese C; Alzani R; Amici R; Avanzi N; Ballinari D; Bischoff J; Borghi D; Casale E; Croci V; Fiorentini F; Isacchi A; Mercurio C; Nesi M; Orsini P; Pastori W; Pesenti E; Pevarello P; Roussel P; Varasi M; Volpi D; Vulpetti A; Ciomei M
    Bioorg Med Chem; 2010 Mar; 18(5):1844-53. PubMed ID: 20153204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diarylureas and diarylamides with pyrrolo[2,3-d]pyrimidine scaffold as broad-spectrum anticancer agents.
    El-Gamal MI; Oh CH
    Chem Pharm Bull (Tokyo); 2014; 62(1):25-34. PubMed ID: 24390490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New diarylureas and diarylamides containing 1,3,4-triarylpyrazole scaffold: Synthesis, antiproliferative evaluation against melanoma cell lines, ERK kinase inhibition, and molecular docking studies.
    Choi WK; El-Gamal MI; Choi HS; Baek D; Oh CH
    Eur J Med Chem; 2011 Dec; 46(12):5754-62. PubMed ID: 22014559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of novel pyrrolo[2,3-b]pyridine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
    Tang Q; Wang L; Tu Y; Zhu W; Luo R; Tu Q; Wang P; Wu C; Gong P; Zheng P
    Bioorg Med Chem Lett; 2016 Apr; 26(7):1680-4. PubMed ID: 26923692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis and biological evaluation of 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine derivatives as c-Met inhibitors.
    Liu N; Wang Y; Huang G; Ji C; Fan W; Li H; Cheng Y; Tian H
    Bioorg Chem; 2016 Apr; 65():146-58. PubMed ID: 26950400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis of novel amides based on acridone scaffold with interesting antineoplastic activity.
    Mahajan AA; Rane RA; Amritkar AA; Naphade SS; Miniyar PB; Bangalore PK; Karpoormath R
    Anticancer Agents Med Chem; 2015; 15(5):555-64. PubMed ID: 25469511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis, in vitro antiproliferative activity, and kinase inhibitory effects of pyrazole-containing diarylureas and diarylamides.
    El-Gamal MI; Park BJ; Oh CH
    Eur J Med Chem; 2018 Aug; 156():230-239. PubMed ID: 30006168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of cytotoxic activity of a series of 1H-pyrrolo[2,3-b]pyridine derivatives as possible inhibitors of c-Met using molecular fingerprints.
    Damghani T; Mashayekh K; Pirhadi S; Firuzi O; Sharifi S; Edraki N; Khoshneviszadeh M; Avestan MS
    J Recept Signal Transduct Res; 2019 Aug; 39(4):295-303. PubMed ID: 31658862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and synthesis of new anticancer pyrimidines with multiple-kinase inhibitory effect.
    El-Deeb IM; Lee SH
    Bioorg Med Chem; 2010 Jun; 18(11):3860-74. PubMed ID: 20471842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis of functionalized amino acid derivatives as new pharmacophores for designing anticancer agents.
    Kumar V; Mudgal MM; Rani N; Jha A; Jaggi M; Singh AT; Sanna VK; Singh P; Sharma PK; Irchhaiya R; Burman AC
    J Enzyme Inhib Med Chem; 2009 Jun; 24(3):763-70. PubMed ID: 18720190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and antitumor activity of 5-[1-(3-(dimethylamino)propyl)-5-halogenated-2-oxoindolin-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxamides.
    Lv K; Wang LL; Liu ML; Zhou XB; Fan SY; Liu HY; Zheng ZB; Li S
    Bioorg Med Chem Lett; 2011 May; 21(10):3062-5. PubMed ID: 21450463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Irreversible inhibitors of the epidermal growth factor receptor: thienopyrimidine core with α,β-unsaturated amide side chain.
    Yang XL; Wang TC; Lin S; Fan HX
    Arch Pharm (Weinheim); 2014 Aug; 347(8):552-8. PubMed ID: 24917121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Guanidinium-based derivatives: searching for new kinase inhibitors.
    Diez-Cecilia E; Kelly B; Perez C; Zisterer DM; Nevin DK; Lloyd DG; Rozas I
    Eur J Med Chem; 2014 Jun; 81():427-41. PubMed ID: 24858546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno[2,3-d]pyrimidines as irreversible epidermal growth factor receptor inhibitors.
    Ji X; Peng T; Zhang X; Li J; Yang W; Tong L; Qu R; Jiang H; Ding J; Xie H; Liu H
    Bioorg Med Chem; 2014 Apr; 22(7):2366-78. PubMed ID: 24565969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
    Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
    Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pyridyl and thiazolyl bisamide CSF-1R inhibitors for the treatment of cancer.
    Scott DA; Aquila BM; Bebernitz GA; Cook DJ; Dakin LA; Deegan TL; Hattersley MM; Ioannidis S; Lyne PD; Omer CA; Ye M; Zheng X
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4794-7. PubMed ID: 18694641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.